Remove Containment Remove Development Remove DNA Remove Protein
article thumbnail

Researchers teach AI to tailor artificial DNA for drug development

Drug Discovery World

Using artificial intelligence, researchers at Chalmers University of Technology, Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. . The technology can contribute to the development and production of vaccines and drugs for severe diseases much faster and at lower cost. .

DNA 52
article thumbnail

How misplaced DNA could influence disease risk

Medical Xpress

DNA is our body's instruction manual. It contains all the information that our cells need to make proteins and other molecules vital for our development, growth and survival.

DNA 56
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. . PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins.

Protein 126
article thumbnail

COVID prompts another milestone, as India clears first DNA vaccine

pharmaphorum

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98
article thumbnail

Traditional Meat Industry’s Beef With Alternative Protein Continues with the FAIR on Labels Act

FDA Law Blog

Gaulkin & Riëtte van Laack — As readers of this blog know, there is a lot of contention about the naming of alternative protein products (APPs), including both plant-based and cell-cultured alternatives for (traditional) animal products. By Sophia R.

Protein 59
article thumbnail

Radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

The Pharma Data

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74. Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio. Disclaimer.

Protein 52
article thumbnail

Leading innovators in coronavirus vaccine components

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The vaccine also contains other inactive ingredients such as cholesterol.